LAUSR

T Prostate cancer is the most prevalent cancer in men and the second leading cause of oncologic death, despite the opportunistic screening conducted and an increasingly frequent diagnosis in the early stages of the disease. Patients with advanced prostate carcinoma mostly undergo androgenic suppression. With this hormonal treatment, temporary remissions are achieved with a mean response of 2--3 years, depending on the tumor burden and the biological profile of the tumor. When the treatment ceases to be effective, it reaches the so-called castration-resistant phase (CRPC). Because there are many controversies and unanswered questions, members of the Spanish Association of Urology with experience in this field have met to create a document regarding the definition of castration-resistant patients to approximate some treatment and follow-up recommendations depending on the characteristics of the disease and creating patient profiles for it. This document has also been embodied in a computer application that enables updates when they occur. Scientific evidence from different clinical practice guidelines (National Comprehensive Cancer Network,1 European Association of Urology2 and American Urological Association3), as well as the most relevant publications on the diagnosis, treatment and follow-up of these patients, has been reviewed.